CLINICAL OUTCOME OF AN PROSPECTIVE, MULTICENTRE, RANDOMIZED, PHASE III NON‐INFERIORITY CLINICAL TRIAL FOR PATIENTS WITH EXTRANODAL NK/T CELL LYMPHOMA TREATED BY P‐GEMOX OR AspaMetDex. (12th June 2019)